Strides Pharma Science shares jumped more than 2% after getting USFDA approval for Theophylline Extended-Release tablets.
In the exchange filing the company said, “Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the generic version of Theophylline Extended-Release Tablets, 300 mg and 450 mg, from the United States Food & Drug Administration (USFDA).”
Strides Pharma Science stock opened at ₹1,352.00. The stock hit a day high of ₹1,389.35 and a low of ₹1,344.85. The company’s market capitalization reached ₹12,668.16 crore.
As of 10:26 am, Strides Pharma Science shares were trading 2.48% higher at Rs 1,378.25 on the NSE.
